AVN-101: A Multi-Target Drug Candidate for the Treatment of CNS Disorders. - Wikidata - awgldk - TriplyDB

AVN-101: A Multi-Target Drug Candidate for the Treatment of CNS Disorders.

AVN-101: A Multi-Target Drug Candidate for the Treatment of CNS Disorders.

http://www.wikidata.org/entity/Q30377178

about

AVN-492, A Novel Highly Selective 5-HT6R Antagonist: Preclinical Evaluation.Serotonin 5-HT6 Receptor Antagonists in Alzheimer's Disease: Therapeutic Rationale and Current Development Status.Engaging sulfinate salts via Ni/photoredox dual catalysis enables facile Csp2 -SO2R coupling.5HT6 Antagonists in the Treatment of Alzheimer's Dementia: Current Progress.

P2860

Q38760655-E7CB324B-8110-4A6E-B2C6-7A0B033F30B3 Q39134334-198F5D41-86B2-44E9-816E-9465A393DDC4 Q55114099-7F57A78D-0628-4132-BA80-38A3C385270E Q55208636-C2F9CC5E-599F-4731-8C78-E81ADCBE485A

P2860

AVN-101: A Multi-Target Drug Candidate for the Treatment of CNS Disorders.

http://www.wikidata.org/entity/Q30377178

description

2016 nî lūn-bûn

@nan

2016 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

AVN-101: A Multi-Target Drug Candidate for the Treatment of CNS Disorders.

@ast

AVN-101: A Multi-Target Drug Candidate for the Treatment of CNS Disorders.

@en

type

label

AVN-101: A Multi-Target Drug Candidate for the Treatment of CNS Disorders.

@ast

AVN-101: A Multi-Target Drug Candidate for the Treatment of CNS Disorders.

@en

prefLabel

AVN-101: A Multi-Target Drug Candidate for the Treatment of CNS Disorders.

@ast

AVN-101: A Multi-Target Drug Candidate for the Treatment of CNS Disorders.

@en

P1433

Q30377178-AFD5D6E6-FAFD-459C-83DE-89EF34DAA618

P1476

Q30377178-18CAA474-4DC0-4F83-9E93-AEB134CA7926

P2093

Q30377178-801EF914-50B5-4F3B-9B78-DD77FC09FE3B

Q30377178-8D0FD7E4-2B43-4E65-9961-D89B18969714

Q30377178-D93AD954-CF19-4916-B87E-A7504949CD89

P275

Q30377178-63646343-D56D-4011-8560-C3B75D7B47FA

P2860

Q30377178-0173B8E1-9616-49BD-A215-EC158C4CB9D6

Q30377178-05521EFC-D1D5-4373-9FF3-ABF29E715664

Q30377178-05CA6AB3-4F96-46DF-BF95-7B89BC5EFD3D

Q30377178-071D47B8-B5D8-46CE-9272-3677E02875F7

Q30377178-0A19FE98-D8A6-4D9A-A42C-F6BA37B78CDE

Q30377178-0A9C47D8-97EF-492C-9273-3EAC79445C68

Q30377178-0CCA1174-5955-45BA-80F8-B8463C04F596

Q30377178-10859C11-AA13-4168-8A33-350B9A7C41B1

Q30377178-130B155F-9F12-4840-A0B0-7574D57569D1

Q30377178-19209F46-9354-4D89-B5B4-3BE4C0C8ABCE

P304

Q30377178-84A143DE-B78C-4F4C-87D1-DECA57F08FAC

P31

Q30377178-7354A9A7-F7C6-40AF-8281-F567B75789FC

Q30377178-BE77A878-512D-42C5-8958-59E680ACC619

P356

Q30377178-D8B17D66-68ED-4E67-BCA6-B1D3AD194A63

P433

Q30377178-FF1DCDAA-5A8A-474B-8583-747573007312

P478

Q30377178-5E52BE63-252A-44D1-A33A-50BB9A2CDBD3

P5008

Q30377178-19F436D5-858A-431A-854C-31857FDE0C30

P577

Q30377178-6C60D412-99FB-40FB-9E19-F9E0B29FAE59

P698

Q30377178-7F90A60B-7D74-4304-9742-13097B706AC8

P921

Q30377178-066FAF46-8B5D-49F6-8300-EDF1A2D64FC5

Q30377178-1353EB23-F85C-45E0-AD5D-BF0E75F76D41

Q30377178-191B1B2E-C88C-4394-9B55-21882E969BA5

Q30377178-3D59DD80-1079-4F25-B314-271FFE83A23B

Q30377178-41C4F661-CC5E-4EF2-9D58-C419EF0B046E

Q30377178-CBBA90C8-9867-430A-956A-8225FD66E439

P932

Q30377178-EEEA98E9-D509-47A5-834A-33309145199F

P356

P1433

Journal of Alzheimer's Disease

P1476

AVN-101: A Multi-Target Drug Candidate for the Treatment of CNS Disorders.

@en

P2093

Alexandre V Ivachtchenko

http://www.w3.org/2001/XMLSchema#string

Ilya Okun

http://www.w3.org/2001/XMLSchema#string

Yan Lavrovsky

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial 4.0 License

P2860

Molecular cloning, characterization, and localization of a high-affinity serotonin receptor (5-HT7) activating cAMP formation

An improved bacterial test system for the detection and classification of mutagens and carcinogens

5-HT6 receptors and Alzheimer's disease

Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013

Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications

The physiological role of 5-HT2A receptors in working memory

International Union of Pharmacology. XIII. Classification of histamine receptors

A novel rat serotonin (5-HT6) receptor: molecular cloning, localization and stimulation of cAMP accumulation

Using an animal model of deficient sensorimotor gating to study the pathophysiology and new treatments of schizophrenia

5-HT6 receptor antagonists as novel cognitive enhancing agents for Alzheimer's disease

P304

583-620

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3233/JAD-151146

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

53

http://www.w3.org/2001/XMLSchema#string

P5008

P577

2016-05-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27232215

http://www.w3.org/2001/XMLSchema#string

P921

cell surface receptor

mechanism of action

membrane proteins

central nervous system disease

biomedical investigative technique

P932

4969713

http://www.w3.org/2001/XMLSchema#string